COVID‐19 vaccine–associated vitiligo: A cross‐sectional study in a tertiary referral center and systematic review

Abstract

AbstractAs the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus continues to infect patients globally, vaccination remains one of the primary methods to combat this prolonged pandemic. However, there are growing reports of coronavirus disease 2019 (COVID‐19) vaccines possibly triggering autoimmunity, irrespective of the vaccine's design. This phenomenon has been observed in patients with vitiligo, with a rising number of cases reporting new‐onset or worsening vitiligo following COVID‐19 vaccinations. In this study, the authors present the most extensive case series of COVID‐19 vaccine–associated vitiligo to date, along with a systematic review of the literature. The aim is to assist physicians in the clinical evaluation of patients with vitiligo with regard to future vaccinations.